AI Overview
Learn more
The outlook for KRM-II-81 under RespireRx appears positive, with preclinical studies showing promising potential as a novel treatment for pharmacoresistant epilepsy due to its ability to suppress epileptiform activity in brain slices from patients with treatment-resistant epilepsy, alongside demonstrating significant analgesic effects with minimal side effects like sedation or tolerance development, making it a potential new drug for managing severe pain conditions as well.
Key points about KRM-II-81:
Mechanism of Action:
KRM-II-81 acts as a positive allosteric modulator of the a2/3-containing GABA receptor, enhancing its activity and leading to increased inhibitory neurotransmission, which could be beneficial in managing seizures and pain.
Preclinical efficacy:
Studies in animal models of pharmacoresistant epilepsy have shown KRM-II-81 to be effective in suppressing seizures with minimal side effects compared to standard antiepileptic drugs.
Patient tissue studies:
Research has demonstrated KRM-II-81's ability to suppress hyperactivity in cortical slices from patients with pharmacoresistant epilepsy, further supporting its potential clinical translation.
Pain management potential:
Preclinical data also indicates KRM-II-81's analgesic properties, showing significant pain relief without the associated risks of opioid dependence or respiratory depression.
Potential challenges:
Clinical trials needed:
While preclinical results are promising, further clinical trials are required to confirm efficacy and safety in human patients.
Regulatory pathway:
Navigating the regulatory process for a new drug can be complex and time-consuming.
Overall, KRM-II-81 under RespireRx holds significant potential as a new treatment option for patients with pharmacoresistant epilepsy and potentially other pain conditions based on its preclinical data demonstrating potent anti-seizure and analgesic effects with a favorable safety profile.
Structural Analogs of the GABAkine KRM-II-81 Are Orally ...
Laboratory of Antiepileptic Drug Discovery, St. ... KRM-II-81 is active in models predicting efficacy in pharmacoresistant epileps...
National Institutes of Health (NIH) (.gov)
RespireRx Pharmaceuticals Inc. Announces Publication of ...
Nov 30, 2021 — (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that scientists associated with the Company have ...
BioSpace
RespireRx Pharmaceuticals Inc. Announces a Department of ...
May 29, 2024 — In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM- II-81 to dr...
RespireRx
Show all
Generative AI is experimental.
Bullish
AI
